{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-10-30",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 2
    }
  },
  "results": [
    {
      "discontinued_date": "04/22/2026",
      "update_type": "New",
      "initial_posting_date": "04/22/2026",
      "package_ndc": "0069-0188-21",
      "generic_name": "Palbociclib Capsule",
      "contact_info": "800-533-4535",
      "related_info": "Discontinuation of the manufacturing of the capsule presentation. 100 mg Tablet NDC 0069-0486-03 will continue to be manufactured.",
      "openfda": {
        "application_number": [
          "NDA207103"
        ],
        "brand_name": [
          "IBRANCE"
        ],
        "generic_name": [
          "PALBOCICLIB"
        ],
        "manufacturer_name": [
          "Pfizer Laboratories Div Pfizer Inc"
        ],
        "product_ndc": [
          "0069-0188",
          "0069-0187",
          "0069-0189"
        ],
        "product_type": [
          "HUMAN PRESCRIPTION DRUG"
        ],
        "route": [
          "ORAL"
        ],
        "substance_name": [
          "PALBOCICLIB"
        ],
        "rxcui": [
          "1601380",
          "1601386",
          "1601388",
          "1601390",
          "1601392",
          "1601394"
        ],
        "spl_id": [
          "7dcc9b87-0aa4-4a00-aced-96be3553e8ac"
        ],
        "spl_set_id": [
          "e0e6412f-50b4-4fd4-9364-62818d121a07"
        ],
        "package_ndc": [
          "0069-0187-21",
          "0069-0188-21",
          "0069-0189-21"
        ],
        "nui": [
          "N0000175605",
          "N0000175082",
          "N0000190114"
        ],
        "pharm_class_epc": [
          "Kinase Inhibitor [EPC]"
        ],
        "pharm_class_moa": [
          "Kinase Inhibitors [MoA]",
          "Cytochrome P450 3A Inhibitors [MoA]"
        ],
        "unii": [
          "G9ZF61LE7G"
        ]
      },
      "update_date": "04/22/2026",
      "therapeutic_category": [
        "Oncology"
      ],
      "dosage_form": "Capsule",
      "presentation": "Ibrance, Capsule, 100 mg (NDC 0069-0188-21)",
      "company_name": "Pfizer Inc.",
      "status": "To Be Discontinued"
    }
  ]
}